Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Abroad (travel likely)Recruiting

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Cancer Hospital & Institute, Beijing, Beijing Municipality, China
Contact: Study coordinator (Anhui Shi) · anhuidoctor@163.com · 8601088196087
Contact: Study coordinator (Jiayi Yu) · 8601088196087

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Toripalimab · Surufatinib · Chemoradiotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Limited-stage Small Cell Lung Cancer (LS-SCLC) · Chemoradiotherapy · Induction Therapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Serplulimab Combined With CCRT for LS-SCLC.

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Abroad (travel likely)RecruitingPHASE3

Goodyear, United States · Tucson, United States